1. Academic Validation
  2. Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF3) derivatives as potential anticancer agents

Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF3) derivatives as potential anticancer agents

  • Eur J Med Chem. 2020 Dec 15;208:112864. doi: 10.1016/j.ejmech.2020.112864.
Xianran He 1 Min Zhong 2 Shaolei Li 3 Xiaolong Li 3 Yiyan Li 4 Zhongtang Li 4 Yangguang Gao 1 Fei Ding 1 Dan Wen 1 Yuchen Lei 2 Yongmin Zhang 5
Affiliations

Affiliations

  • 1 Institute for Interdisciplinary Research, Jianghan University, Wuhan Economic and Technological Development Zone, Wuhan, 430056, China.
  • 2 School of Chemical and Environmental Engineering, Jianghan University, Wuhan Economic and Technological Development Zone, Wuhan, 430056, China.
  • 3 Shenzhen Fushan Biological Technology Co., Ltd, Kexing Science Park A1 1005, Nanshan Zone, Shenzhen, 518057, China.
  • 4 State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
  • 5 Institute for Interdisciplinary Research, Jianghan University, Wuhan Economic and Technological Development Zone, Wuhan, 430056, China; Institut Parisien de Chimie Moléculaire, UMR 8232, CNRS, Sorbonne Université, 4 Place Jussieu, 75005, Paris, France. Electronic address: yongmin.zhang@upmc.fr.
Abstract

A series of organoselenium compounds based on the hybridization of nonsteroidal antiinflammatory drugs (NSAIDs) scaffolds and Se functionalities (-SeCN and -SeCF3) were synthesized and characterized, and evaluated against four types of Cancer cell lines, SW480 (human colon adenocarcinoma cells), HeLa (human cervical Cancer cells), A549 (human lung carcinoma cells), MCF-7 (human breast adenocarcinoma cells). Interestingly, most of the investigated compounds showed active in reducing the viability of different Cancer cell lines. The most active compound 3h showed IC50 values lower than 20 μM against the four Cancer cell lines, particularly to SW480 and MCF-7 with IC 50 values of 4.9 and 3.4 μM, respectively. Furthermore, NSAIDs-SeCN derivatives (2h and 2i) and NSAIDs-SeCF3 derivatives (3h and 3i) were selected to investigate their ability to induce Apoptosis in MCF-7 cells via modulation the expression of anti-apoptotic Bcl-2 protein, pro-inflammatory cytokines (IL-2) and proapoptotic Caspase-3 protein. Moreover, the redox properties of the synthesized organoselenium candidates were conducted by 2, 2-didiphenyl-1-picrylhydrazyl (DPPH), bleomycin dependent DNA damage and Glutathione Peroxidase (GPx)-like assays. Taken together, these NSAIDs-Se candidates could provide promising new lead derivatives for further potential Anticancer drug development.

Keywords

Anticancer; NSAIDs; Selenocyanates; Trifluoromethyl selenides.

Figures
Products